Contact
searchSearch
HMP Global
Login

20S Proteasome Videos

Dr Laubach
Videos
Dr Laubach Reviews Phase 2 GRIFFIN Study Results in Newly Diagnosed MM
01/10/2022
Jacob Laubach, MD, MPP, Dana-Farber Cancer Institute, discusses new results from the Phase 2 GRIFFIN study of daratumumab as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the ASH 2021 Annual Meeting.
Jacob Laubach, MD, MPP, Dana-Farber Cancer Institute, discusses new results from the Phase 2 GRIFFIN study of daratumumab as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the ASH 2021 Annual Meeting.
Jacob Laubach, MD, MPP,...
01/10/2022
Oncology
Dr M
Videos
Dr Mithraprabhu Discusses Liquid Biopsy to Define Genomic Characteristics of Patients With MM
12/02/2021
Dr Sridurga Mithraprabhu, discusses liquid biopsy, which can be utilized to define the genomic characteristics of a patient with MM.
Dr Sridurga Mithraprabhu, discusses liquid biopsy, which can be utilized to define the genomic characteristics of a patient with MM.
Dr Sridurga Mithraprabhu,...
12/02/2021
Oncology
Dr Dimopoulos
Videos
Daratumumab-Based Triplet Therapy More Effective Than Doublet for MM
09/15/2021
Meletios Dimopoulos, MD, discusses the phase 3 APOLLO study on adding daratumumab to pomalidomide and low-dose dexamethasone for patients with MM.
Meletios Dimopoulos, MD, discusses the phase 3 APOLLO study on adding daratumumab to pomalidomide and low-dose dexamethasone for patients with MM.
Meletios Dimopoulos, MD,...
09/15/2021
Oncology
Dr Jain Discusses High-Risk MCL: Definition, Current Challenges, and Management
Videos
Dr Jain Discusses High-Risk MCL: Definition, Current Challenges, and Management
02/09/2021
Preetesh Jain, MBBS, MD, DM, PhD, discusses a study that explores the definition, current challenges, and management of high-risk MCL.
Preetesh Jain, MBBS, MD, DM, PhD, discusses a study that explores the definition, current challenges, and management of high-risk MCL.
Preetesh Jain, MBBS, MD, DM,...
02/09/2021
Oncology
Dr Tam Discusses Ibrutinib Therapy Plus Venetoclax for R/R MCL
Videos
Dr Tam Discusses Ibrutinib Therapy Plus Venetoclax for R/R MCL
12/07/2020
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, discusses highlights from, "Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study", presented...
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, discusses highlights from, "Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study", presented...
Constantine Tam, MBBS (Hons),...
12/07/2020
Oncology
Ajai Chari, MD, Talks Talquetamab for Relapsed/Refractory MM
Videos
Ajai Chari, MD, Talks Talquetamab for Relapsed/Refractory MM
12/05/2020
In this video, Dr Chari discusses the findings of a phase 1 trial examining the use of talquetamab in heavily pretreated patients with relapsed/refractory MM.
In this video, Dr Chari discusses the findings of a phase 1 trial examining the use of talquetamab in heavily pretreated patients with relapsed/refractory MM.
In this video, Dr Chari...
12/05/2020
Oncology
Benefits and Risks of Cell Therapies for Relapsed/Refractory MCL
Videos
Benefits and Risks of Cell Therapies for Relapsed/Refractory MCL
04/24/2020
Mehdi Hamadani, MD, weighs the pros and cons of allogeneic stem cell transplant and CAR-T therapy as salvage options for patients with MCL.
Mehdi Hamadani, MD, weighs the pros and cons of allogeneic stem cell transplant and CAR-T therapy as salvage options for patients with MCL.
Mehdi Hamadani, MD, weighs the...
04/24/2020
Oncology
Videos
Immunotherapies in Multiple Myeloma
10/25/2019
David E. Avigan, MD discusses active immunotherapies for the treatment of multiple myeloma.
David E. Avigan, MD discusses active immunotherapies for the treatment of multiple myeloma.
David E. Avigan, MD discusses...
10/25/2019
Oncology
Videos
Key Insights in Multiple Myeloma
02/27/2018
Drs Morton Coleman and Ruben Niesvizky summarize the key take-home points presented on multiple myeloma during Lymphoma & Myeloma 2016.
Drs Morton Coleman and Ruben Niesvizky summarize the key take-home points presented on multiple myeloma during Lymphoma & Myeloma 2016.
Drs Morton Coleman and Ruben...
02/27/2018
Oncology

Recent News

News
Datopotamab Deruxtecan Approved for HR-Positive, HER2-Negative Breast Cancer
01/17/2025
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug...
01/17/2025
Oncology
FDA Alerts
Sotorasib Plus Panitumumab Approved for Patients With KRAS G12C-Mutated Colorectal Cancer
01/17/2025
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Based on results from the phase...
01/17/2025
Oncology
FDA Approval
FDA Approves Acalabrutinib With Bendamustine and Rituximab for Patients With Previously Untreated MCL
01/17/2025
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
The FDA granted approval to...
01/17/2025
Oncology
News
Presence of Circulating Lymphoma Cells May Be Associated With Worse Survival Outcomes for Newly Diagnosed Patients With DLBCL
01/16/2025
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are...
01/16/2025
Oncology
News
Ciltacabtagene Autoleucel Demonstrates Efficacy for Patients With R/R Multiple Myeloma in Real-World Population
01/15/2025
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene...
01/15/2025
Oncology
News
Addition of Nab-Paclitaxel to Standard Gemcitabine and Cisplatin Did Not Significantly Improve Survival for Patients With Newly Diagnosed Biliary Tract Cancer
01/14/2025
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the...
01/14/2025
Oncology
News
First-line Eribulin Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer
01/14/2025
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the...
01/14/2025
Oncology
News
Avelumab Plus Axitinib Demonstrates Long-Term Efficacy, Safety for Patients With Advanced Renal Cell Carcinoma
01/08/2025
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3...
01/08/2025
Oncology
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
Nivolumab Plus Ipilimumab Prolonged Progression-Free Survival for Patients with MSI-H/dMMR Metastatic Colorectal Cancer
01/06/2025
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
Interim analysis results from...
01/06/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use